Jump to Content

Related Links

GAMMAGARD LIQUID Therapy
Benefits

Studies show that GAMMAGARD LIQUID therapy, the most widely used 10% IVIG1 †, is a specially formulated 10% IVIG therapy with demonstrated efficacy, safety and tolerability for patients – children to adults* – with primary immunodeficiency.2,3

† Based on the number of grams distributed in the US, Jan-Dec 2008.

*Clinical study evaluated patients 6-72 years of age.

TOLERABILITY

Talk to your doctor about the treatment that is appropriate for you.

Learn more at GAMMAGARDLIQUID.com

VIRAL SAFETY

GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] 10% uses plasma collection processes designed to put your safety first. Manufacturing steps eliminate viruses and impurities.3

For added safety and assurance, GAMMAGARD LIQUID therapy is treated with a dedicated 3-step process devoted to viral inactivation/removal.3

dedicated 3-step process devoted to viral inativation/removal

As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated.

Learn more at GAMMAGARDLIQUID.com

EFFICACY

The efficacy of GAMMAGARD LIQUID therapy has been demonstrated in a pivotal open-label clinical study of 61 patients (58 evaluable) with primary immunodeficiency.

These patients were treated with 300 to 600 mg/kg GAMMAGARD LIQUID therapy every 21 to 28 days over a 12-month period. The primary efficacy endpoint of the study was the annualized rate of specified acute serious bacterial infections. There were zero validated acute serious bacterial infections in the clinical study.2,3

Learn more at GAMMAGARDLIQUID.com

PATIENT SUPPORT

GAMMAGARD LIQUID therapy is backed by Baxter's innovative support for patients, including insurance assistance, access programs, and partnerships with patient organizations.

Download the GAMMAGARD LIQUID Brochure

GAMMAGARD LIQUID is indicated for the treatment of primary immunodeficiency disorders associated with defects in humoral immunity. These include but are not limited to congenital X-linked agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Important Risk Information for GAMMAGARD LIQUID

GAMMAGARD LIQUID is contraindicated in patients with known anaphylactic or severe hypersensitivity responses to Immune Globulin (Human). Patients with severe selective IgA deficiency (IgA < 0.05 g/L) may develop anti-IgA antibodies that can result in a severe anaphylactic reaction.

Immune Globulin Intravenous (Human) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death. Patients predisposed to acute renal failure include patients with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Especially in such patients, IGIV products should be administered at the minimum concentration available and the minimum rate of infusion practicable. While these reports of renal dysfunction and acute renal failure have been associated with the use of many of the licensed IGIV products, those containing sucrose as a stabilizer accounted for a disproportionate share of the total number.

Glycine, an amino acid, is used as a stabilizer. GAMMAGARD LIQUID does not contain sucrose.

GAMMAGARD LIQUID is made from human plasma. It may carry a risk of transmitting infectious agents, e.g. viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Components used in the packaging of this product are latex-free.

Thrombotic events have been reported in association with IGIV. Patients at risk may include those with a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, and/or known or suspected hyperviscosity, hypercoagulable disorders, and prolonged periods of immobilization.

IGIV products can contain blood group antibodies that may cause a positive direct antiglobulin reaction and, rarely, hemolysis.

Aseptic meningitis syndrome (AMS) has been reported to occur infrequently in association with IGIV treatment. Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae.

Various mild and moderate reactions, such as headache, fever, fatigue, chills, flushing, dizziness, urticaria, wheezing or chest tightness, nausea, vomiting, rigors, back pain, chest pain, muscle cramps, and changes in blood pressure may occur with infusions of Immune Globulin Intravenous (Human).

Please see the Full Prescribing Information for GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] for full prescribing details.

  1. The Marketing Research Bureau. The Plasma Fractions Market in the United States 2008. Orange, CT: Marketing Research Bureau, 2009.
  2. Church JA, Leibl H, Stein MR, Melamed I, Rubinstein A, Schneider L, Wasserman R, Pavlova B, Birthistle K, Mancini M, Fritsch S, Patrone L, Moore-Perry K, Ehrlich H, and the US-PID-IGIV 10% Study Group. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. Journal of Clinical Immunology 2006; 26:388-395.
  3. GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] 10% package insert. Westlake Village, CA. Baxter International Inc.; October 2009.